N@N

Syneron Added to Russell Indexes

^{Published on 2010-06-29 09:10:33 - Market Wire}
 

YOKNEAM, ISRAEL--(Marketwire - June 29, 2010) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, announced today that it has been added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes, effective June 25, 2010 after the close of the U.S. markets.

Louis P. Scafuri, Chief Executive Officer, commented, "We are pleased that Syneron is now included in the Russell Indexes, broadening our exposure to the institutional and retail investment communities. The addition comes at an important point in the Company's growth trajectory, as we work to leverage the benefits of our merger with Candela, increase adoption of our recently launched product platforms, and advance our pipeline of innovative aesthetic products to address the changing needs of both physicians and patients."

The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the last trading day in May, ranking them by total market capitalization. The Russell 3000 includes the largest 3,000 of these stocks and automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007. The Russell Microcap Index is comprised of the smallest 1,000 stocks in the Russell 2000 Index plus the next smallest 1,000 stocks. Membership in the Russell Indexes, which remains in place for one year, is determined primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in assets currently are benchmarked to them.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at [ www.syneron.com ].